Trials / Completed
CompletedNCT03927170
Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)
A Randomized, Open-label, Fed, Single Dose, Crossover Study to Compare the Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- GL Pharm Tech Corporation · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
Crossover study to compare the pharmacokinetic characteristics of GLH1SM sustained release tablet and Janumet XR tablet in fed condition
Detailed description
2 X 2 crossover study to compare the pharmacokinetic characteristics and safety of GLH1SM sustained release 100/1000mg tablet and Janumet XR 100/1000mg tablet
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Janumet XR tablet 100/1000 mg | To administrate the Janumet XR tablet |
| COMBINATION_PRODUCT | GLH1SM tablet 100/1000 mg | To administrate the GLH1SM tablet |
Timeline
- Start date
- 2019-05-02
- Primary completion
- 2019-09-11
- Completion
- 2019-10-23
- First posted
- 2019-04-25
- Last updated
- 2020-07-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03927170. Inclusion in this directory is not an endorsement.